Table 14 Number of Italian patients taking pharmacological treatment prior to, and during, medical cannabis therapy
From: Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series
| N = 18 | N = 12 | |||
|---|---|---|---|---|
| Prior to MC therapy | At a 3-month MC therapy | At a 3-month MC therapy | At a 12-month MC therapy | |
| Analgesic medication | ||||
| Acetaminophen (ACE) | 4 (22.2%) | 1 (5.5%) | 1 (8.3%) | 0 |
| NSAIDs | 3 (16.6%) | 2 (11.1%) | 1 (8.3%) | 0 |
| Steroids | 1 (5.5%) | 1 (5.5%) | 1 (8.3%) | 1 (8.3%) |
| Weak opioids | 2 (11.1%) | 2 (11.1%) | 2 (16.6%) | 0 |
| Strong opioids | 5 (27.7%) | 3 (16.6%) | 3 (25%) | 0 |
| Drug | ||||
| Amitriptyline | 0 | 0 | 0 | 0 |
| Gabapentin | 0 | 0 | 0 | 0 |
| Pregabalin | 6 (33.3%) | 3 (16.6%) | 2 (16.6%) | 1 (8.3%) |
| Duloxetine | 7 (38.8%) | 6 (33.3%) | 5 (41.6) | 3 (25%) |
| Venlafaxine | 2 (11.1%) | 1 (5.5%) | 1 (8.3%) | 0 |
| Milnacipran | 1 (5.5%) | 1 (5.5%) | 0 | 0 |
| Benzodiazepines | 7 (38.8%) | 2 (11.1%) | 2 (16.6%) | 1 (8.3%) |
| Muscle relaxants | 1 (5.5%) | 0 | 0 | 0 |
| No drugs | 0 | 6 (33.3%) | 6 (33.3%) | 8 (66.7%) |